Keywords
How to Cite
Abstract
Colorectal cancer remains one of the most common tumors. In the structure of cancer mortality in Russia, tumors of this localization occupy the second place among persons of both sexes, giving way to the cancer of the trachea and bronchi in men, and breast cancer in women, respectively. Despite modern diagnostic methods and approaches to treatment, the problem of colorectal cancer remains acute due to increasing morbidity throughout the world, and recently there has been a downward trend in the average age of patients, which increases the social significance of the problem. According to the modern concept of carcinogenesis, assessment of the influence of genetic factors on the development of tumors of this localization looks very promising. Research aimed at finding a connection between genetic markers, single-nucleotide polymorphisms of genes and their contribution to the problem of colorectal cancer is one of the most studied directions in modern oncology. In this review, the work done related to the role of gene polymorphisms in the development and therapy of colorectal cancer was evaluated. The works were searched for in the databases of PubMed and Cyber Leninka. The known data about some genes participating in different processes of human organism are given. The data on sensitization and protective effects of polymorphisms of genes, the effect of polymorphisms on the result of treatment of colorectal cancer are presented. The necessity of further work in this direction in order to search for genetic markers and the possibility of implementing the definition of gene polymorphism in clinical practice for personalization of treatment of patients with colorectal cancer are discussed.
References
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019 [Kaprin A.D., Starinskii V.V., Petrova G.V. Malignant tumors of Russia in 2018 (morbidity and mortality). Moscow, 2019. (in Russ).].
American Cancer Society. Colorectal Cancer Facts & Figures 2017–2019. Atlanta, Ga: American Cancer Society; 2017.
Федоров В.Э., Поделякин К.А. Эпидемиологические аспекты колоректального рака // Медицинский альманах. 2017;49(4):145–148 [Fedorov V.E., Podelyakin K.A. Epidemiological aspects of colorectal cancer // Medical almanac. 2017;4(49):145–148. (in Russ).]
Imyanitov EN, Togo AV, Hanson KP. Searching for cancer-associated gene polymorphisms: promises and obstacles // Cancer Lett. 2004;204:3–14.
Заридзе Д.Г. Канцерогенез. М.: Медицина, 2004 [Zaridze D.G. Kancerogenez. Moscow: Meditsina; 2004 (in Russ)].
Иллариошкин С.Н., Скоблов М.Ю., Исламов Р.Р. и др. Медицинская генетика. Часть 3. Полиморфизм генов. Прямая ДНК-диагностика. Частота мутантных генов в популяции. Учебно-методическое пособие. Казань: КГМУ, 2014 [Illarioshkin S.N., SkoblovM.Yu., Islamov R.R. et al. Medicinskayagenetika. CHast' 3. Polimorfizmgenov. Pryamaya DNK-diagnostika. Chastotamutantnyhgenov v populyacii. Uchebno-metodicheskoeposobie. Kazan': KGMU; 2014. (in Russ)].
Brookes AJ.. The essence of SNP // Gene. 1999;234:177–186. https: // doi: org/10.1016/S0378-1119(99)00219-X
Дмитриева А.И., Серебрякова В.А., Кузнецова И.А. и др. Исследование полиморфизмов гена XPD A751C у больных раком легкого с разными клинико-морфологическими характеристиками опухоли // Вопросы онкологии. 2016;62(3):470–472 [Dmitrieva A.I., Serebryakova V.A., Kuznecova I.A. et al. The study of polymorphisms of XPD gene A751C in lung cancer patients with different clinical and morphological characteristics of tumor // Problems in oncology. 2016;62(3):470–473. (in Russ)].
Jin D, Zhang M, Hua H. Impact of polymorphisms in DNA repair genes XPD, hOGG1 and XRCC4 on colorectal cancer risk in a Chinese Han Population // Biosci Rep. 2019 Jan 15;39(1):BSR20181074. https: // doi: 10.1042/BSR20181074
Mucha B, Pytel D, Markiewicz L et al. Nucleotide Excision Repair Capacity and XPC and XPD Gene Polymorphism Modulate Colorectal Cancer Risk // Clin Colorectal Cancer. 2018 Jun;17(2):e435-e441. https: // doi: 10.1016/j.clcc.2016.10.001
Ramireddy L, Chen WT, Peng CT et al. Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan // J Clin Lab Anal. 2015;29(4):268–274. https: // doi: 10.1002/jcla.21763
Gunathilake MN, Lee J, Cho YA et al. Interaction between physical activity, PITX1 rs647161 genetic polymorphism and colorectal cancer risk in a Korean population: a case-control study [published correction appears in Oncotarget. 2018 Oct 9;9(79):35027] // Oncotarget. 2018;9(7):7590–7603. https: // doi: 10.18632/oncotarget.24136
Liu J, Zheng B, Li Y et al. Genetic Polymorphisms of DNA Repair Pathways in Sporadic Colorectal Carcinogenesis // J Cancer. 2019;10(6):1417–1433. https: // doi: 10.7150/jca.28406
Куликов Е.П., Мерцалов С.А., Никифоров А.А. и др. Полиморфизм гена XPD при колоректальном раке // Наука молодых (Eruditio Juvenium). 2019;7(3):340–348. https: // doi: 10.23888/HMJ201973340-348 [Kulikov E.P., Mertsalov S.A., Nikiforov A.A. et al. Polymorphism of XPD gene in colorectal cancer // Science of the young (Eruditio Juvenium). 2019;7(3):340–8. https: // doi: 10.23888/HMJ201973340-348 (in Russ)].
Jiang J, Xie Z, Guo J et al. Association of PPARG rs 1801282 C>G polymorphism with risk of colorectal cancer: from a case-control study to a meta-analysis // Oncotarget. 2017;8(59):100558-100569. https: // doi: 10.18632/oncotarget.20138
Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor // Cell. 1994;79:1147–1156.
Elrod HA, Sun SY. PPARgamma and Apoptosis in Cancer // PPAR Res. 2008;2008:704165.
Girnun GD, Smith WM, Drori S et al. APC-dependent suppression of colon carcinogenesis by PPARgamma // Proc Natl Acad Sci USA. 2002;99:13771–13776.
Wang W, Shao Y, Tang S et al. Peroxisome proliferator-activated receptor-gamma (PPARgamma) Pro12Ala polymorphism and colorectal cancer (CRC) risk // Int J ClinExp Med. 2015;8:4066–4072.
Wei Z, Han G, Bai X. Effect of Proliferator-Activated Receptor-gamma Pro12Ala Polymorphism on Colorectal Cancer Risk: A Meta-Analysis // Med Sci Monit. 2015;21:1611–1616.
Jiang J, Gajalakshmi V, Wang J et al. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population // Cancer Sci. 2005;96:507–512.
Kuriki K, Hirose K, Matsuo K et al. Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese // Cancer Sci. 2006;97:1226–1235.
Koh WP, Yuan JM, Van Den Berg D et al. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore // Carcinogenesis. 2006;27:1797–1802.
Zhang YC, Zhao H, Chen C et al. COX-2 gene rs689466 polymorphism is associated with increased risk of colorectal cancer among Caucasians: a meta-analysis // World J Surg Oncol. 2020;18(1):192. https: // doi: 10.1186/s12957-020-01957-x
Peng L, Zhou Y, Wang Y et al. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature // PLoS One. 2013;8(3):e58891.
Li M, Tan SY, Wang XF. Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE (2) synthesis and COX-2 expression // Oncol Rep. 2014;32(6):2845–53.
Che XH, Chen CL, Ye XL et al. Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro // Oncol Rep. 2016;35(3):1680–8.
Pereira C, Sousa H, Silva J et al. The -1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines // Mol Carcinog. 2014;53(Suppl 1):E92–5.
Ruan Y, Sun J, Wu F et al. Relationship between COX-2 gene polymorphism and the risk of colorectal cancer // Int J Digest Dis. 2013;11(04):260–372.
Pereira C, Queiros S, Galaghar A et al. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development // PLoS One. 2014;9(4):e92000.
Shomaf M, Yousef AL, Ababna N et al. Cyclooxygenase-2 (COX2) gene polymorphisms and the risk of sporadic colorectal cancer and polyps among Jordanian population // Turk J Gastroenterol. 2015;26(2):154–8.
Lu X, Xiao S, Jin C et al. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis // Journal of clinicallaboratory analysis. 26(1), 10–15. https: // doi: org/10.1002/jcla.20494
Kap EJ, Seibold P, Scherer D et al. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients // Int J Cancer. 2016;138(12):2993–3001. https: // doi: 10.1002/ijc.30026
Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al. Methylenetetrahydrofolatereductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients // British journal of clinical pharmacology. 69(1):58–66. https: // doi: org/10.1111/j.1365-2125.2009.03556.x
Куликов Е.П., Судаков А.И., Никифоров А.А. и др. Значение полиморфизма генов в развитии колоректального рака // Российский медико-биологический вестник им. академика И.П. Павлова. 2020;28(2):127–134. https: // doi: 10.23888/PAVLOVJ2020282127-134 [Kulikov E.P., Sudakov A.I., Nikiforov A.A. et al. Significance of gene polymorphysm in development of colorectal cancer // I.P. Pavlov Russian Medical Biological Herald. 2020;28(2):127–134. https: // doi: 10.23888/PAVLOVJ2020282127-134 (in Russ)].
Ura K, Hayes JJ. Nucleotide excision repair and chromatin remodeling // Eur J Biochem. 2002 May;269(9):2288–93. https: // doi: 10.1046/j.1432-1033.2002.02888.x
Petit C, Sancar A. Nucleotide excision repair: from E. coli to man // Biochimie. 1999 Jan-Feb;81(1–2):15–25. https: // doi: 10.1016/s0300-9084(99)80034-0
Yulan J, Xueyun F. Research progress about correlation of XPD/ ERCC2 polymorphism with sensitivity to diseases // Ind Health Occup Dis. 2007;33:109–112 (inChinese).
Paré L, Marcuello E, Altés A et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy // Br J Cancer. 2008 Oct 7;99(7):1050–5. https: // doi: 10.1038/sj.bjc.6604671
Park DJ, Stoehlmacher J, Zhang W et al. A Xerodermapigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer // Cancer Res. 2001 Dec 15;61(24):8654–8.
Lai JI, Tzeng CH, Chen PM et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma // Cancer Sci. 2009 Jul;100(7):1261–6. https: // doi: 10.1111/j.1349-7006.2009.01186.x
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021